Financial Performance - The company's operating revenue for Q3 2024 reached RMB 10,449,076,271.75, representing a year-on-year increase of 12.30%[4] - Net profit attributable to shareholders for the same period was RMB 785,843,766.10, showing a significant increase of 55.43% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 582,174,869.86, reflecting a substantial increase of 474.77% compared to the previous year[4] - The net cash flow from operating activities for Q3 2024 was RMB 1,079,633,457.17, an increase of 65.68% year-on-year[4] - Basic earnings per share for the quarter were RMB 0.29, up 52.63% from the same period last year[4] - Diluted earnings per share also stood at RMB 0.29, marking a 52.63% increase year-on-year[4] Assets and Liabilities - Total assets at the end of the reporting period were RMB 115,264,761,757.14, a year-on-year increase of 1.58%[5] - Equity attributable to shareholders at the end of the reporting period was RMB 47,301,473,095.24, reflecting a growth of 3.54% compared to the previous year[5] - Current assets totaled RMB 34.53 billion, up from RMB 33.79 billion, indicating a growth of about 2.18%[27] - Short-term borrowings increased to RMB 18.68 billion from RMB 14.73 billion, representing a rise of approximately 26.67%[28] - Total liabilities decreased slightly to RMB 56.07 billion from RMB 56.85 billion, a decline of about 1.37%[28] - The total owner's equity rose to RMB 59.19 billion from RMB 56.62 billion, an increase of approximately 4.53%[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 262,536[10] - Shanghai Fosun High Technology (Group) Co., Ltd. holds 889,890,955 shares, accounting for 33.30% of the total shares[10] - HKSCC Nominees Limited holds 551,372,815 shares, representing 20.63% of the total shares[10] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder holding over 889 million shares[11] - The company has a diverse shareholder base, including domestic and foreign institutional investors[10] - The report indicates that there are no shares under pledge or frozen status for the major shareholders[10] Research and Development - Research and development investment totaled RMB 3.915 billion in the first three quarters of 2024, with RMB 2.648 billion allocated specifically for R&D expenses[14] - The company is focusing on innovative drugs and high-value medical devices, continuously promoting lean operations and cost reduction[13] - The company is implementing an open R&D model, including the establishment and management of industrial funds to support the incubation and investment of R&D projects[14] - The company has prioritized key projects in its R&D management to ensure efficient results transformation and continuous launch of innovative products[14] Clinical Trials and Approvals - The company received IND approval for the injectable A-type botulinum toxin (brand name: Daxif) for the treatment of moderate to severe glabellar lines in China[17] - The company’s innovative anti-HER2 monoclonal antibody HLX22 showed significant improvement in first-line treatment for HER2-positive advanced or metastatic gastric/gastroesophageal junction cancer in a Phase II clinical trial[17] - The company’s HLX11 (recombinant anti-HER2 monoclonal antibody) entered Phase II clinical trials for the treatment of HER2-positive and HR-negative early or locally advanced breast cancer[15] - The company’s SBK 010 oral solution received IND approval for the treatment of mild to moderate acute ischemic stroke[15] - The company’s 23-valent pneumococcal polysaccharide vaccine received approval for Phase I and III clinical trials for the prevention of pneumococcal diseases in China[16] - The company’s freeze-dried human rabies vaccine received IND approval for Phase I and III clinical trials for rabies prevention[16] Financial Activities - Fosun Pharma increased its stake in Kite Pharma to 100%, acquiring an additional 50% equity, which will be consolidated into the group's financial statements[19] - The company completed an A-share repurchase plan, buying back 5,677,700 shares, approximately 0.21% of total shares, for a total amount of about RMB 126.64 million[20] - The H-share repurchase plan saw the company buy back 5,471,500 shares, about 0.20% of total shares, with a total expenditure of approximately HKD 66.9 million[21] - The controlling shareholder, Fosun High Technology, increased its holdings by 4,295,000 A-shares, representing 0.16% of total shares, with a total investment of approximately RMB 101.19 million[22] Comprehensive Income - The company reported a total comprehensive income of RMB 2.30 billion for the first three quarters of 2024, down from RMB 3.04 billion in 2023, a decline of about 24.1%[30] - The comprehensive income total for the first three quarters of 2024 was CNY 1.24 billion, compared to CNY 943.78 million in the same period of 2023, reflecting an increase of approximately 31.5%[36] Cash Flow - The company reported a decrease in other comprehensive income to RMB -1.47 billion from RMB -1.30 billion, reflecting a decline of approximately 12.69%[28] - The total cash inflow from investment activities was RMB 1,823,762,368.12, down 41.8% from RMB 3,127,265,876.22 in the first three quarters of 2023[32] - The net cash flow from financing activities was negative RMB 502,289,412.69, compared to a negative RMB 396,579,604.48 in the same period of 2023[32] - The company received RMB 21,739,468,572.59 in loans during the first three quarters of 2024, compared to RMB 18,051,361,530.05 in the same period of 2023, marking an increase of 20.5%[32]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 召開2024 年第三季度業績說明會的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 吳以芳 中國，上海 2024 年1 0 月2 9 日 於本公告日期，本公司之執行董事為吳以芳先生、王可心先生、關曉暉女士及文德鏞先生；本公司之非執 行董事為陳 啟 宇先生、徐曉亮先生、潘東輝先生及陳玉卿先生；以及本公司之獨立非執行董事為李玲女士、 湯谷良先生、王全弟先生及余梓山先生。 * 僅供識別 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 证券 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司股權激勵計劃實施進展暨關聯交易的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 吳以芳 证券代码：600196 股票简称：复星医药 编号：临 2024-166 上海复星医药（集团）股份有限公司 关于控股子公司股权激励计划实施进展 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《2024 年第三季度報告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 重要内容提示： 董事長 吳以芳 中國，上海 2024 年1 0 月2 9 日 於本公告日期，本公司之執行董事為吳以芳先生、王可心先生、關曉暉女士及文德鏞先生；本公司之非執 行董事為陳 啟 宇先生、徐曉亮先生、潘東輝先生及陳玉卿先生；以及本公司之獨立非執行董事為李玲女士、 湯谷良先生、王全弟先生及余梓山先生。 * 僅供識別 上海复星医 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《第九 屆董事會第六十四次會議（定期會議）決議公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 吳以芳 中國，上海 2024 年1 0 月2 9 日 * 僅供識別 证券代码：600196 股票简称：复星医药 编号：临 2024-165 上海复星医药（集团）股份有限公司 第九届董事会第六十四次会议（定期会议）决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏 ...

证券代码：600196 股票简称：复星医药 编号：临 2024-166 上海复星医药（集团）股份有限公司 关于控股子公司股权激励计划实施进展 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 ●交易概述： 因李胜利先生已辞去复星健康董事职务，2024 年 10 月 29 日，本公司董事会批 准根据 2022 年 2 月已采纳的复星健康股权激励计划以人民币 156.5659 万元回购李 胜利先生已获授但尚未归属的对应人民币 150 万元复星健康注册资本（约占截至本 公告日期复星健康注册资本总额的 0.0283%）的跟投（即本次回购）。 2022 年 2 月 11 日，本公司董事会及控股子公司复星健康股东会分别批准采纳 复星健康股权激励计划，本计划激励工具为跟投和限制性股权单位，所涉激励权益 对应不超过截至 2022 年 2 月 11 日复星健康注册资本总额（即人民币 380,435 万元， 下同）的 8%（约占截至本公告日期<即 2024 年 10 月 29 日，下同>复星健康注册资 本总额<即人民 ...

证券代码：600196 股票简称：复星医药 编号：临 2024-167 上海复星医药（集团）股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） ●召开时间：2024 年 11 月 13 日(星期三)下午 16:00-17:00 ●召开方式：网络互动 ●互动网址：上证路演中心（https://roadshow.sseinfo.com） ●投资者可于 2024 年 11 月 6 日(星期三)至 11 月 12 日(星期二)16:00 期间登 录上证路演中心网站首页点击"提问预征集"栏目进行提问，或将问题以电子邮件 形式发送至本公司投资者关系邮箱 ir@fosunpharma.com。本公司将于业绩说明会上 就投资者普遍关注的问题进行回答。 上海复星医药（集团）股份有限公司（以下简称"本公司"）于 2024 年 10 月 30 日披露 2024 年第三季度报告。为了便于广大投资者更全面深入地了解本集团（即 本公司及控股子公司/单位，下同）2024 ...

第九届董事会第六十四次会议（定期会议）决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海复星医药（集团）股份有限公司（以下简称"本公司"）第九届董事会 第六十四次会议（定期会议）于2024年10月29日在上海市宜山路1289号会议室以 现场与通讯（视频会议）相结合方式召开，应到会董事12人，实到会董事12人。 会议由本公司执行董事、董事长吴以芳先生主持，本公司监事列席了会议。本次 会议的召开符合《中华人民共和国公司法》、其他有关法律法规和《上海复星医 药（集团）股份有限公司章程》的规定。会议审议并通过如下议案： 一、审议通过本集团（即本公司及控股子公司/单位，下同）2024 年第三季度 报告。 证券代码：600196 股票简称：复星医药 编号：临 2024-165 上海复星医药（集团）股份有限公司 1 同时，同意授权本公司管理层或其授权人士处理与本次回购相关的具体事宜， 包括但不限于签署、修订并执行相关协议。 由于李胜利先生系本公司过去 12 个月内离任高级管理人员，根据《上海证券 交易所股票上市规则》的规定，其构 ...

Financial Performance - The company's operating revenue for Q3 2024 reached ¥10,449,076,271.75, representing a year-on-year increase of 12.30%[5] - Net profit attributable to shareholders for Q3 2024 was ¥785,843,766.10, a significant increase of 55.43% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥582,174,869.86, showing a remarkable increase of 474.77% year-on-year[5] - Basic earnings per share for Q3 2024 were ¥0.29, up by 52.63% year-on-year[5] - For the first three quarters of 2024, the company achieved operating revenue of 30.912 billion RMB, a year-on-year increase of 0.69%, and a 5.74% increase excluding COVID-related products[12] - The net profit attributable to shareholders of the listed company was 2.011 billion RMB, with a year-on-year growth of 24.58% for the net profit after deducting non-recurring gains and losses, amounting to 1.836 billion RMB[12] - The total comprehensive income for the first three quarters of 2024 was CNY 2,304,590,338.15, down from CNY 3,036,856,754.24 in the previous year[30] Cash Flow - The net cash flow from operating activities for Q3 2024 was ¥1,079,633,457.17, reflecting a growth of 65.68% compared to the previous year[5] - The net cash flow from operating activities reached 2.987 billion RMB, reflecting a year-on-year increase of 21.33%[12] - In the first three quarters of 2024, the company reported operating cash inflows of approximately CNY 31.55 billion, a decrease of 5.6% compared to CNY 33.44 billion in the same period of 2023[32] - The net cash flow from operating activities for the first three quarters of 2024 is approximately -¥300.05 million, a significant decrease from ¥302.87 million in the same period of 2023[40] - The total cash inflow from financing activities in the first three quarters of 2024 is approximately ¥17.01 billion, while the cash outflow is approximately ¥16.81 billion, resulting in a net cash flow of approximately ¥202.24 million[40] Assets and Liabilities - Total assets as of September 30, 2024, amounted to ¥115,264,761,757.14, an increase of 1.58% from the end of the previous year[5] - The company reported a total liability of CNY 56,070,157,587.51, slightly down from CNY 56,853,344,377.17 year-over-year[28] - The company's total liabilities increased to CNY 14.43 billion as of September 30, 2024, up from CNY 13.42 billion at the end of 2023, marking a rise of 7.5%[36] - The total equity of the company reached CNY 35.45 billion as of September 30, 2024, compared to CNY 35.12 billion at the end of 2023, showing an increase of 0.9%[36] Research and Development - Research and development investment totaled 3.915 billion RMB, with R&D expenses accounting for 2.648 billion RMB in the first three quarters of 2024[12] - The company is focusing on innovative drugs and high-value medical devices, while promoting lean operations and cost reduction[12] - The company is implementing an open R&D model to ensure the sustainability of drug innovation and development[12] - The company has made significant progress in its R&D pipeline, with multiple products entering various clinical trial phases, including HLX11 reaching the primary endpoint of Phase III trials for HER2-positive breast cancer[13] - The company’s innovative anti-HER2 monoclonal antibody HLX22 demonstrated controllable safety in clinical trials, enhancing treatment outcomes for patients[15] Shareholder Information - The controlling shareholder, Fosun High Technology, held a total of 961,424,455 shares, representing approximately 35.98% of the company's total shares as of the end of the reporting period[10] - The top ten shareholders collectively held 1,186,000,000 shares, accounting for 44.43% of the total shares[10] - The controlling shareholder plans to increase their stake by at least RMB 100 million within 12 months, with a maximum increase of 2% of the total shares[21] - As of September 12, 2024, the controlling shareholder has acquired 4,295,000 A shares, representing about 0.16% of the total shares, with a total investment of approximately RMB 101.19 million[21] Investment Activities - The company experienced a decline in investment income from joint ventures, impacting overall profitability[6] - The company reported a significant increase in investment income, amounting to CNY 1.59 billion in 2024, although it was lower than CNY 1.79 billion in 2023, indicating a decrease of 10.5%[37] - The company’s investment activities resulted in a net cash outflow of approximately -¥272.68 million in the first three quarters of 2024, compared to a net inflow of ¥387.52 million in the same period of 2023[40] Share Repurchase - The company completed its A-share repurchase plan, buying back 5,677,700 shares, approximately 0.21% of its total shares, for a total amount of approximately 126.64 million yuan[18] - The company has approved the repurchase and cancellation of 1,072,246 restricted A shares, totaling approximately RMB 22.83 million[23] - Following the cancellation of the restricted shares, the total number of shares will decrease from 2,672,398,711 to 2,671,326,465[24] - The company has repurchased a total of 5,471,500 H shares, accounting for approximately 0.20% of the total shares outstanding as of the reporting date[19] - The total amount spent on the H share repurchase is approximately HKD 66.9 million, excluding transaction costs[20]

香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本聯合公告全部或任何部份內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責任。 本聯合公告僅供參考，並不構成收購、購買或認購任何證券之邀請或要約，亦非在任何司法管轄區招攬任何 投票或批准。 本聯合公告不會在構成違反任何司法管轄區相關法律的情況下於或向有關司法管轄區發佈、刊發或派發。 上 海 復 宏 漢 霖 生 物 技 術 股 份 有 限 公 司 （ 於中華人民共和國註冊成立的股份有限公司 ） （股份代號：02696） 上 海 復 星 新 藥 研 究 股 份 有 限 公 司 （ 於中華人民共和國註冊成立的股份有限公司 ） 聯合公告 內容有關以吸收合併復宏漢霖之方式 由復星新藥對 復宏漢霖附前提條件私有化之建議之最新進展 要約人的牽頭財務顧問 要約人的聯席財務顧問 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Henlius Biotech, Inc. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ...